TO ASSESS THE EFFICACY OF NAPROXEN AND SULFASALAZINE IN SUBJECTS WITH JUVENILE ONSET ANKYLOSING SPONDYLITIS (10-17 YEARS): A PROSPECTIVE STUDY

Bansal Yogesh

Bansal Yogesh

Keywords

Juvenile onset of Ankylosing spondylitis, inflammatory markers, Sulfasalazine, Naproxen

Abstract

Background – Juvenile onset Ankylosing Spondylitis(JoAS) damages joints, inflames the spine, breaks bones, and causes back pain. Our study's objective was to evaluate the development of JoAS symptoms utilizing sophisticated inflammatory indicators.

Materials and methods: For this prospective study, three groups of 21 JOAS participants were created. Three men and two women made up Group A. There were four males and four females in each of the two groups, Group B and Group C. A placebo was given to Group A, 1000 mg of naproxen was given to Group B each day, and 2000 mg of sulfasalazine was given to Group C each day. BASFI, BASDAI, and BASGI scores of four were accepted by the study. JoAS was also connected to MMP-3, ICAM-1, IL-6, IL-17, TNF α, and IL-6. JoAS biomarker measures were taken at baseline and at six weeks in Groups A, B, and C. The levels of CRP, TNF α, IL-6, and MMP-3 in groups A, B, and C were compared.

Results - For TNF α -, IL-6, and MMP-3, the medication response was significantly greater in group C than in group B. IL-6 levels declined threefold in group C from baseline (p = 0.01) to the 6th week (p = 0.001). TNF α levels in groups B and C were lower than in group A. (p 0.01, p 0.001).

Conclusion IL-6 and TNF α are cytokines that may have a role in the immunopathogenesis of JoAS. We also believe that these cytokines can be utilized to make diagnoses and gauge the success of treatments. Sulfasalazine treats JoAS better than naproxen.

Abstract 46 | pdf Downloads 27

References

1. Bal, A., Unlu, E., Bahar, G., Aydog, E., Eksioglu, E., & Yorgancioglu, R. (2007a). Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clinical Rheumatology, 26(2), 211–215. https://doi.org/10.1007/S10067-006-0283-5
2. Bal, A., Unlu, E., Bahar, G., Aydog, E., Eksioglu, E., & Yorgancioglu, R. (2007b). Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis. Clinical Rheumatology, 26(2), 211–215. https://doi.org/10.1007/S10067-006-0283-5
3. Brandt, J., Listing, J., Sieper, J., Rudwaleit, M., Van Der Heijde, D., & Braun, J. (2004). Development and preselection of criteria for short term improvement after anti-TNF α treatment in ankylosing spondylitis. Annals of the Rheumatic Diseases, 63(11), 1438–1444. https://doi.org/ 10. 1136/ARD.2003.016717
4. Burgos-Vargas, R. (2009). A case of childhood-onset ankylosing spondylitis: Diagnosis and treatment. Nature Clinical Practice Rheumatology, 5(1), 52–57. https://doi.org/ 10. 1038/ncprheum0971
5. Chen, J., Veras, M. M. S., Liu, C., & Lin, J. (2013). Methotrexate for ankylosing spondylitis. Cochrane Database of Systematic Reviews, 2013(2). https://doi.org/ 10.1002/ 14651858. CD004524.pub4
6. Colebatch, A. N., Marks, J. L., & Edwards, C. J. (2011). Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database of Systematic Reviews. https://doi.org/10.1002/ 14651858.cd008872.pub2
7. Conti, F., Ceccarelli, F., Marocchi, E., Magrini, L., Spinelli, F. R., Spadaro, A., Scrivo, R., & Valesini, G. (2007). Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Annals of the Rheumatic Diseases, 66(10), 1393–1397. https://doi.org/10.1136/ ARD. 2007.073569
8. De Vries, M. K., Van Eijk, I. C., Van Der Horst-Bruinsma, I. E., Peters, M. J. L., Nurmohamed, M. T., Dijkmans, B. A. C., Hazenberg, B. P. C., & Wolbink, G. J. (2009a). Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis and Rheumatism, 61(11), 1484–1490. https://doi.org/10.1002/ART.24838
9. De Vries, M. K., Van Eijk, I. C., Van Der Horst-Bruinsma, I. E., Peters, M. J. L., Nurmohamed, M. T., Dijkmans, B. A. C., Hazenberg, B. P. C., & Wolbink, G. J. (2009b). Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Care and Research, 61(11), 1484–1490. https://doi.org/10.1002/art.24838
10. El Miedany, Y., Youssef, S., Mehanna, A., Shebrya, N., Gamra, S. A., & El Gaafary, M. (2008). Defining disease status in ankylosing spondylitis: Validation and cross-cultural adaptation of the Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Global score (BASG). Clinical Rheumatology, 27(5), 605–612. https://doi.org/10.1007/s10067-007-0755-2
11. Heuft-Dorenbosch, L., Van Tubergen, A., Spoorenberg, A., Landewé, R., Dougados, M., Mielants, H., Van Der Tempel, H., & Van Der Heijde, D. (2004). The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis and Rheumatism, 51(2), 154–159. https://doi.org/10.1002/ART.20233
12. HILL, H. F. H., & HILL, A. G. S. (1975). Ankylosing Spondylitis: Open Long‐Term and Double‐Blind Crossover Studies with Naproxen. The Journal of Clinical Pharmacology, 15(4), 355–362. https://doi.org/10.1002/j.1552-4604. 1975. t b01464.x
13. Jadon, D. R., Ramanan, A. V., & Sengupta, R. (2013). Juvenile versus adult-onset ankylosing spondylitis - Clinical, radiographic, and social outcomes. a systematic review. Journal of Rheumatology, 40(11), 1797–1804. https://doi. org/10.3899/jrheum.130542
14. Maksymowych, W. P., Landewé, R., Conner-Spady, B., Dougados, M., Mielants, H., Van Der Tempel, H., Poole, A. R., Wang, N., & Van Der Heijde, D. (2007). Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis and Rheumatism, 56(6), 1846–1853. https://doi.org/10.1002/ART.22589
15. Peloso, P. M., Gammaitoni, A., Smugar, S. S., Wang, H., & Moore, A. R. (2011). Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis. BMC Musculoskeletal Disorders, 12. https:// doi.org/ 10.1186/1471-2474-12-165
16. Rudwaleit, M., Listing, J., Brandt, J., Braun, J., & Sieper, J. (2004). Prediction of a major clinical (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Annals of the Rheumatic Diseases, 63(6), 665–670. https://doi.org/ 10. 1136/ard.2003.016386
17. Song, I. H., Rudwaleit, M., Listing, J., & Sieper, J. (2009a). Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Annals of the Rheumatic Diseases, 68(11), 1701–1707. https:// doi. org/10.1136/ard.2008.099226
18. Song, I. H., Rudwaleit, M., Listing, J., & Sieper, J. (2009b). Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Annals of the Rheumatic Diseases, 68(11), 1701–1707. https:// doi.org/10.1136/ard.2008.099226
19. Taylor, W. J., & Harrison, A. A. (2004). Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Care and Research, 51(3), 311–315. https://doi.org/10.1002/art.20421
20. Zochling, J. (2011). Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI). Arthritis Care and Research, 63(SUPPL. 11), S47–S58. https:// doi. org/10.1002/acr.20575

pdf

Published

Sep 11, 2015

How to Cite

Bansal Yogesh. (2015). TO ASSESS THE EFFICACY OF NAPROXEN AND SULFASALAZINE IN SUBJECTS WITH JUVENILE ONSET ANKYLOSING SPONDYLITIS (10-17 YEARS): A PROSPECTIVE STUDY. Journal of Population Therapeutics and Clinical Pharmacology, 22(3), 303–309. Retrieved from https://jptcp.com/index.php/jptcp/article/view/3402